Immunovant, Inc.
IMVT$1.87B
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaNEW YORK362 employees
Drugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Aug 15, 2026
19wMarket Overview
Stock performance and key metrics
IMVT News
Catalyst Timeline
1 upcoming, 1 past
Drug Pipeline
IMVT-1402
Chronic Inflammatory Demyelinating Polyneuropathy
Batoclimab
Thyroid Eye Disease
Batoclimab 680 mg SC weekly
Generalized Myasthenia Gravis
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly
Chronic Inflammatory Demyelinating Polyneuropathy
RVT-1401
Myasthenia Gravis
IMVT-1401 (batoclimab)
Graves Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMVT-1402 | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
Batoclimab | Phase 3 | Thyroid Eye Disease | - | - |
Batoclimab 680 mg SC weekly | Phase 3 | Generalized Myasthenia Gravis | - | - |
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
RVT-1401 | Phase 2 | Myasthenia Gravis | - | - |
IMVT-1401 (batoclimab) | Phase 2 | Graves Disease | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply